Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Simon Baker CFA
RR
Simon Baker CFA
Rothschild & Co Redburn
Wall Street Analyst
★★★☆☆
#1766
on 13Foresight · ranked by our own returns
33%
Success Rate
-12.2%
Average Return
3 of 9 calls profitable · -15.6% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 33% of Simon Baker CFA's ratings turned a profit when each position was held for 1 year — averaging -12.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

3 Buy 0 Hold 0 Sell
Simon's Stock Coverage 12 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NVO
Novo Nordisk
 Sep 16, 2025 BUY Buy
+168.8% avg upside
26 analysts
 — -21.1%
GILD
Gilead Sciences
 Sep 12, 2025 BUY Strong Buy
-4.8% avg upside
66 analysts
$143.00
15.57% Upside
 +10.8%
REGN
Regeneron
 Aug 14, 2025 BUY Strong Buy
+26.9% avg upside
57 analysts
$890.00
45.85% Upside
 +8.0%
AUTL
Autolus Therapeutics
 Nov 15, 2024 BUY Strong Buy
+605.8% avg upside
16 analysts
$13.00
761.02% Upside
 -55.5%
GB:0QIU
Novo Nordisk
 Nov 08, 2024 HOLD Hold
+43.2% avg upside
28 analysts
$600.00
104.53% Upside
 ·
FR:IPN
Ipsen
 Jun 15, 2024 BUY Buy
-21.9% avg upside
17 analysts
$165.00
5.36% Upside
 ·
CH:NOVN
Novartis AG
 Nov 27, 2023 SELL Buy
-9.8% avg upside
30 analysts
$80.00
32.38% Downside
 ·
BNTX
BioNTech SE
 May 17, 2023 BUY Strong Buy
+50.5% avg upside
26 analysts
$170.00
87.07% Upside
 -13.8%
MRNA
Moderna
 Feb 01, 2022 HOLD Hold
+6.1% avg upside
38 analysts
 — +0.9%
QGEN
Qiagen
 Oct 14, 2021 BUY Buy
+14.1% avg upside
23 analysts
 — -15.8%
ABT
Abbott Laboratories
 Oct 14, 2021 HOLD Strong Buy
+31.2% avg upside
35 analysts
 — -12.7%
CH:ROP
Roche Holding AG
 Apr 01, 2020 BUY Buy
+3.3% avg upside
23 analysts
 — ·
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Simon Baker CFA — Frequently Asked Questions
How accurate are Simon Baker CFA's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Simon's ratings were profitable over a one-year hold, with an average return of -12.2% per rating, or -15.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Simon ranked on 13Foresight?
Simon Baker CFA is currently ranked #1766 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Simon cover?
Simon most recently has ratings on NVO, GILD, REGN, AUTL, GB:0QIU, FR:IPN, CH:NOVN, BNTX, MRNA, QGEN, ABT, CH:ROP. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.